Flow Cytometry Market

The flow cytometry market is projected to reach USD 10.57 billion by 2034 from USD 5.56 billion in 2026, at a CAGR of 8.4% during the forecast period.

To know about the assumptions considered for the study download the pdf brochure

BD (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sony Corporation (Japan), Miltenyi Biotec (Germany), and Revvity (US) are the key players in this market. These market players have adopted various approaches, including product launches, collaborations, acquisitions, agreements, and expansions, to enhance their market positions.

• In January 2026, BD launched an updated BD Research Cloud featuring BD Horizon Panel Maker, an AI-powered automated panel-design tool intended to improve the design, quality, and efficiency of high-parameter flow cytometry experiments in areas including immunology and cancer research.
• In September 2025, Beckman Coulter Life Sciences launched IR820 and IR870, the industry's first directly conjugated antibodies for infrared excitation. The reagents are designed to reduce spectral overlap and background interference, supporting more flexible high-parameter flow cytometry panel design and human phenotyping studies.

BD (US) is a leading provider of flow cytometry instruments, reagents, antibodies, assays, and associated workflow solutions through its BD Biosciences portfolio. Its major platforms include the BD FACSymphony, BD FACSLyric, BD FACSMelody, and BD Accuri product families, supporting applications ranging from routine cell analysis to high-parameter research and cell sorting. The company also offers an extensive portfolio of fluorochrome-conjugated antibodies and multicolor panel solutions used for immunophenotyping and other cellular analyses. BD's flow cytometry solutions are widely used in immunology, oncology, hematology, infectious disease research, clinical diagnostics, and drug discovery, with continued emphasis on high-parameter analysis, workflow automation, and standardized cellular characterization.

Danaher Corporation (US) participates in the flow cytometry market primarily through Beckman Coulter Life Sciences, which provides research and clinical flow cytometers, reagents, antibodies, and supporting analysis solutions. Its CytoFLEX family includes the CytoFLEX, CytoFLEX S, and CytoFLEX LX systems, with configurations supporting increasingly complex multicolor cellular analysis, while the DxFLEX, Navios EX, and AQUIOS CL platforms address clinical flow cytometry workflows. Beckman Coulter also offers a broad range of flow cytometry antibodies and assay reagents, including products for both research and clinical use. The portfolio supports immunophenotyping, hematologic disease assessment, immune-cell characterization, cell biology research, and high-complexity multicolor analysis across academic, biopharmaceutical, and clinical laboratories.

Thermo Fisher Scientific Inc. (US) offers an integrated flow cytometry portfolio comprising cell analyzers, spectral cell sorters, antibodies, fluorophores, dyes, assays, and related reagents under brands including Invitrogen. Its instrument portfolio includes Attune flow cytometers, including the spectrally enabled Attune Xenith platform, and the Bigfoot Spectral Cell Sorter for high-dimensional cell analysis and sorting. The company complements these systems with a broad selection of flow cytometry antibodies, viability dyes, and functional assay reagents used for multiparameter cellular characterization. Thermo Fisher's solutions support immunology, oncology, cell biology, drug discovery, rare-cell analysis, and cell and gene therapy research, with particular strengths in high-throughput analysis, complex multicolor panels, and spectral flow cytometry workflows.

Market Ranking

The flow cytometry market is highly consolidated, with a few established life sciences and laboratory technology companies accounting for a significant share of global revenues. Key players include BD (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Agilent Technologies, Inc. (US).

BD holds a leading position through its broad BD Biosciences portfolio of flow cytometers, cell sorters, antibodies, fluorophores, assays, and related reagents used across research and clinical applications. Danaher Corporation strengthens its market position through Beckman Coulter Life Sciences, which offers research and clinical flow cytometry systems, antibodies, and assay reagents for multiparameter cellular analysis and immunophenotyping. Thermo Fisher Scientific Inc. competes through its Attune flow cytometry platforms, Bigfoot Spectral Cell Sorter, antibodies, dyes, fluorophores, and functional assay reagents. Agilent Technologies, Inc. enhances the competitive landscape with its NovoCyte flow cytometers and related cell analysis solutions for immunology, oncology, drug discovery, and cell biology research. The strong installed bases, extensive reagent portfolios, broad geographic reach, established customer relationships, and continued technological innovation of these companies create relatively high barriers to entry and reinforce the market's consolidated nature.

Related Reports:

Flow Cytometry Market by Technology (Cell, Bead-based), Product [Cell Analyzer, Sorter, Antibodies, Assays & Kits (Apoptosis), Software], Service, Detection (Spectral), Application (Clinical, Research), End User, Competition - Global Forecast to 2034

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]